Search

Your search keyword '"Iwashyna, Theodore J."' showing total 1,749 results
Start Over Author "Iwashyna, Theodore J."
1,749 results on '"Iwashyna, Theodore J."'

2. Impact of SARS-CoV-2 Infection on Long-Term Depression Symptoms among Veterans

Author

Chen, Jason I., Bui, David, Iwashyna, Theodore J., Shahoumian, Troy A., Hickok, Alex, Shepherd-Banigan, Megan, Hawkins, Eric J., Naylor, Jennifer, Govier, Diana J., Osborne, Thomas F., Smith, Valerie A., Bowling, C. Barrett, Boyko, Edward J., Ioannou, George N., Maciejewski, Matthew L., O’Hare, Ann M., Viglianti, Elizabeth M., Bohnert, Amy S.-B., and Hynes, Denise M.

Published
2024
Full Text
View/download PDF

3. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.

Author

Bajema, Kristina L, Berry, Kristin, Streja, Elani, Rajeevan, Nallakkandi, Li, Yuli, Mutalik, Pradeep, Yan, Lei, Cunningham, Francesca, Hynes, Denise M, Rowneki, Mazhgan, Bohnert, Amy, Boyko, Edward J, Iwashyna, Theodore J, Maciejewski, Matthew L, Osborne, Thomas F, Viglianti, Elizabeth M, Aslan, Mihaela, Huang, Grant D, and Ioannou, George N

Subjects
Humans, Ritonavir, Antiviral Agents, Retrospective Studies, Aged, Veterans, Female, Male, COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Drug Treatment, Clinical Research, Clinical Trials and Supportive Activities, Prevention, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundInformation about the effectiveness of oral antivirals in preventing short- and long-term COVID-19-related outcomes in the setting of Omicron variant transmission and COVID-19 vaccination is limited.ObjectiveTo measure the effectiveness of nirmatrelvir-ritonavir and molnupiravir for outpatient treatment of COVID-19.DesignThree retrospective target trial emulation studies comparing matched cohorts of nirmatrelvir-ritonavir versus no treatment, molnupiravir versus no treatment, and nirmatrelvir-ritonavir versus molnupiravir.SettingVeterans Health Administration (VHA).ParticipantsNonhospitalized veterans in VHA care who were at risk for severe COVID-19 and tested positive for SARS-CoV-2 during January through July 2022.InterventionNirmatrelvir-ritonavir or molnupiravir pharmacotherapy.MeasurementsIncidence of any hospitalization or all-cause mortality at 30 days and from 31 to 180 days.ResultsEighty-seven percent of participants were male; the median age was 66 years, and 18% were unvaccinated. Compared with matched untreated control participants, those treated with nirmatrelvir-ritonavir (n = 9607) had lower 30-day risk for hospitalization (22.07 vs. 30.32 per 1000 participants; risk difference [RD], -8.25 [95% CI, -12.27 to -4.23] per 1000 participants) and death (1.25 vs. 5.47 per 1000 participants; RD, -4.22 [CI, -5.45 to -3.00] per 1000 participants). Among persons alive at day 31, reductions were seen in 31- to 180-day incidence of death (hazard ratio, 0.66 [CI, 0.49 to 0.89]) but not hospitalization (subhazard ratio, 0.90 [CI, 0.79 to 1.02]). Molnupiravir-treated participants (n = 3504) had lower 30-day and 31- to 180-day risks for death (3.14 vs. 13.56 per 1000 participants at 30 days; RD, -10.42 [CI, -13.49 to -7.35] per 1000 participants; hazard ratio at 31 to 180 days, 0.67 [CI, 0.48 to 0.95]) but not hospitalization. A difference in 30-day or 31- to 180-day risk for hospitalization or death was not observed between matched nirmatrelvir- or molnupiravir-treated participants.LimitationThe date of COVID-19 symptom onset for most veterans was unknown.ConclusionNirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and death. Molnupiravir was associated with a benefit for 30-day mortality but not hospitalization. Further reductions in mortality from 31 to 180 days were observed with both antivirals.Primary funding sourceU.S. Department of Veterans Affairs.

Published
2023

4. Risk of Suicide-Related Outcomes After SARS-COV-2 Infection: Results from a Nationwide Observational Matched Cohort of US Veterans

Author

Hynes, Denise M., Niederhausen, Meike, Chen, Jason I., Shahoumian, Troy A., Rowneki, Mazhgan, Hickok, Alex, Shepherd-Banigan, Megan, Hawkins, Eric J., Naylor, Jennifer, Teo, Alan, Govier, Diana J., Berry, Kristin, McCready, Holly, Osborne, Thomas F., Wong, Edwin, Hebert, Paul L., Smith, Valerie A., Bowling, C. Barrett, Boyko, Edward J., Ioannou, George N., Iwashyna, Theodore J., Maciejewski, Matthew L., O’Hare, Ann M., Viglianti, Elizabeth M., and Bohnert, Amy S.-B.

Published
2024
Full Text
View/download PDF

6. In-person peer support for critical care survivors: The ICU REcovery Solutions cO-Led through surVivor Engagement (ICURESOLVE) pilot randomised controlled trial

Author

Haines, Kimberley J., Hibbert, Elizabeth, Skinner, Elizabeth H., Leggett, Nina, Holdsworth, Clare, Ali Abdelhamid, Yasmine, Bates, Samantha, Bicknell, Erin, Booth, Sarah, Carmody, Jacki, Deane, Adam M., Emery, Kate, Farley, K.J., French, Craig, Krol, Lauren, MacLeod-Smith, Belinda, Maher, Lynne, Paykel, Melanie, and Iwashyna, Theodore J.

Published
2024
Full Text
View/download PDF

9. Correction to: Impact of SARS-CoV-2 Infection on Long-Term Depression Symptoms among Veterans

Author

Chen, Jason I., Bui, David, Iwashyna, Theodore J., Shahoumian, Troy A., Hickok, Alex, Shepherd-Banigan, Megan, Hawkins, Eric J., Naylor, Jennifer, Govier, Diana J., Osborne, Thomas F., Smith, Valerie A., Bowling, C. Barrett, Boyko, Edward J., Ioannou, George N., Maciejewski, Matthew L., O’Hare, Ann M., Viglianti, Elizabeth M., Bohnert, Amy S.-B., and Hynes, Denise M.

Published
2024
Full Text
View/download PDF

13. Correction: Design and analysis of outcomes following SARS-CoV-2 infection in veterans

Author

Smith, Valerie A., Berkowitz, Theodore S. Z., Hebert, Paul, Wong, Edwin S., Niederhausen, Meike, Pura, John A., Berry, Kristin, Green, Pamela, Korpak, Anna, Fox, Alexandra, Baraff, Aaron, Hickok, Alex, Shahoumian, Troy A, Bohnert, Amy S.B., Hynes, Denise M., Boyko, Edward J., Ioannou, George N., Iwashyna, Theodore J., Bowling, C. Barrett, O’Hare, Ann M., and Maciejewski, Matthew L.

Published
2023
Full Text
View/download PDF

14. Design and analysis of outcomes following SARS-CoV-2 infection in veterans

Author

Smith, Valerie A., Berkowitz, Theodore S. Z., Hebert, Paul, Wong, Edwin S., Niederhausen, Meike, Pura, John A., Berry, Kristin, Green, Pamela, Korpak, Anna, Fox, Alexandra, Baraff, Aaron, Hickok, Alex, Shahoumian, Troy A, Bohnert, Amy S.B., Hynes, Denise M., Boyko, Edward J., Ioannou, George N., Iwashyna, Theodore J., Bowling, C. Barrett, O’Hare, Ann M., and Maciejewski, Matthew L.

Published
2023
Full Text
View/download PDF

17. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome

Author

Moss, Marc, Huang, David T, Brower, Roy G, Ferguson, Niall D, Ginde, Adit A, Gong, MN, Grissom, Colin K, Gundel, Stephanie, Hayden, Douglas, Hite, R Duncan, Hou, Peter C, Hough, Catherine L, Iwashyna, Theodore J, Khan, Akram, Liu, Kathleen D, Talmor, Daniel, Thompson, B Taylor, Ulysse, Christine A, Yealy, Donald M, and Angus, Derek C

Subjects
Clinical Research, Lung, Bioengineering, Cardiovascular, Acute Respiratory Distress Syndrome, Rare Diseases, Clinical Trials and Supportive Activities, Respiratory, Good Health and Well Being, Adult, Aged, Atracurium, Combined Modality Therapy, Conscious Sedation, Female, Hospital Mortality, Humans, Male, Middle Aged, Neuromuscular Blockade, Neuromuscular Blocking Agents, Positive-Pressure Respiration, Respiratory Distress Syndrome, Treatment Failure, National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThe benefits of early continuous neuromuscular blockade in patients with acute respiratory distress syndrome (ARDS) who are receiving mechanical ventilation remain unclear.MethodsWe randomly assigned patients with moderate-to-severe ARDS (defined by a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of

Published
2019

18. Prospective Assessment of the Feasibility of a Trial of Low-Tidal Volume Ventilation for Patients with Acute Respiratory Failure.

Author

Lanspa, Michael J, Gong, Michelle Ng, Schoenfeld, David A, Lee, Kathleen Tiffany, Grissom, Colin K, Hou, Peter C, Serpa-Neto, Ary, Brown, Samuel M, Iwashyna, Theodore J, Yealy, Donald M, Hough, Catherine L, Brower, Roy G, Calfee, Carolyn S, Hyzy, Robert C, Matthay, Michael A, Miller, Russell R, Steingrub, Jay S, Thompson, B Taylor, Miller, Chadwick D, Clemmer, Terry P, Hendey, Gregory W, Huang, David T, Mathews, Kusum S, Qadir, Nida, Tidswell, Mark, and The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network

Subjects
The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network, Humans, Respiratory Insufficiency, Acute Disease, Tidal Volume, Treatment Outcome, Respiration, Artificial, Incidence, Hospital Mortality, Survival Rate, Follow-Up Studies, Prospective Studies, Feasibility Studies, Middle Aged, Intensive Care Units, United States, Female, Male, Clinical Trials as Topic, acute respiratory distress syndrome, low-stretch ventilation, low–tidal volume ventilation, lung-protective ventilation, mechanical ventilation, Clinical Trials and Supportive Activities, Acute Respiratory Distress Syndrome, Clinical Research, Rare Diseases, Patient Safety, Lung, Respiratory, Good Health and Well Being, low-tidal volume ventilation
Abstract

RationaleLow-tidal volume ventilation (LTVV; 6 ml/kg) benefits patients with acute respiratory distress syndrome and may aid those with other causes of respiratory failure. Current early ventilation practices are poorly defined.ObjectivesWe observed patients with acute respiratory failure to assess the feasibility of a pragmatic trial of LTVV and to guide experimental design.MethodsWe prospectively enrolled consecutive patients with acute respiratory failure admitted to intensive care units expected to participate in the proposed trial. We collected clinical data as well as information on initial and daily ventilator settings and inpatient mortality. We estimated the benefit of LTVV using predictive linear and nonlinear models. We simulated models to estimate power and feasibility of a cluster-randomized trial of LTVV versus usual care in acute respiratory failure.ResultsWe included 2,484 newly mechanically ventilated patients (31% with acute respiratory distress syndrome) from 49 hospitals. Hospital mortality was 28%. Mean initial tidal volume was 7.1 ml/kg predicted body weight (95% confidence interval, 7.1-7.2), with 78% of patients receiving tidal volumes less than or equal to 8 ml/kg. Our models estimated a mortality benefit of 0-2% from LTVV compared with usual care. Simulation of a stepped-wedged cluster-randomized trial suggested that enrollment of 106,361 patients would be necessary to achieve greater than 90% power.ConclusionsUse of initial tidal volumes less than 8 ml/kg predicted body weight was common at hospitals participating in the National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. After considering the size and budgetary requirement for a cluster-randomized trial of LTVV versus usual care in acute respiratory failure, the PETAL Network deemed the proposed trial infeasible. A rapid observational study and simulations to model anticipated power may help better design trials.

Published
2019

20. The impact of distance on post-ICU disability

Author

D'Arcy, Jack, Haines, Kimberley, Paul, Eldho, Doherty, Zakary, Goodwin, Andrew, Bailey, Michael, Barrett, Jonathan, Bellomo, Rinaldo, Bucknall, Tracey, Gabbe, Belinda J., Higgins, Alisa M., Iwashyna, Theodore J., Murray, Lynne J., Myles, Paul S., Ponsford, Jennie, Pilcher, David, Udy, Andrew A., Walker, Craig, Young, Meredith, Cooper, D.J. (Jamie), and Hodgson, Carol L.

Published
2022
Full Text
View/download PDF

22. Extended versus Standard Proning Duration for COVID-19–associated Acute Respiratory Distress Syndrome: A Target Trial Emulation Study.

Author

Hochberg, Chad H., Colantuoni, Elizabeth, Sahetya, Sarina K., Eakin, Michelle N., Fan, Eddy, Psoter, Kevin J., Iwashyna, Theodore J., Needham, Dale M., and Hager, David N.

Subjects
ADULT respiratory distress syndrome, PATIENT positioning, INTENSIVE care units, ELECTRONIC health records, MEDICAL registries
Abstract

Rationale: Prone positioning for ⩾16 hours in moderate-to-severe acute respiratory distress syndrome (ARDS) improves survival. However, the optimal duration of proning is unknown. Objectives: To estimate the effect of extended versus standard proning duration on patients with moderate-to-severe coronavirus disease (COVID-19) ARDS. Methods: Data were extracted from a five-hospital electronic medical record registry. Patients who were proned within 72 hours of mechanical ventilation were categorized as receiving extended (⩾24 h) versus standard (16–24 h) proning based on the first proning session length. We used a target trial emulation design to estimate the effect of extended versus standard proning on the primary outcome of 90-day mortality and secondary outcomes of ventilator liberation and intensive care unit (ICU) discharge. Analytically, we used inverse probability of treatment weighted (IPTW) Cox or Fine-Gray regression models. Results: A total of 314 patients were included; 234 received extended proning, and 80 received standard-duration proning. Patients who received extended proning were older, had greater comorbidity, were more often at an academic hospital, and had shorter time from admission to mechanical ventilation. After IPTW, characteristics were well balanced. Unadjusted 90-day mortality in the extended versus standard proning groups was 39% versus 58%. In doubly robust IPTW analyses, we found no significant effects of extended versus standard proning duration on mortality (hazard ratio [95% confidence interval], 0.95 [0.51–1.77]), ventilator liberation (subdistribution hazard, 1.60 [0.97–2.64], or ICU discharge (subdistribution hazard, 1.31 [0.82–2.10]). Conclusions: Using target trial emulation, we found no significant effect of extended versus standard proning duration on mortality, ventilator liberation, or ICU discharge. However, given the imprecision of estimates, further study is justified. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Regional Variation in Financial Hardship Among US Veterans During the COVID-19 Pandemic

Author

Hauschildt, Katrina E, primary, Bui, David P, additional, Govier, Diana J, additional, Eaton, Tammy L, additional, Viglianti, Elizabeth M, additional, Ettman, Catherine K, additional, McCready, Holly, additional, Smith, Valerie A, additional, O’Hare, Ann M, additional, Osborne, Thomas F, additional, Boyko, Edward J, additional, Ioannou, George N, additional, Maciejewski, Matthew L, additional, Bohnert, Amy S-B, additional, Hynes, Denise M, additional, and Iwashyna, Theodore J, additional

Published
2024
Full Text
View/download PDF

34. Effect of Early High-Dose Vitamin D3 Repletion on Cognitive Outcomes in Critically Ill Adults

Author

Han, Jin H., Ginde, Adit A., Brown, Samuel M., Baughman, Adrienne, Collar, Erin M., Ely, E. Wesley, Gong, Michelle N., Hope, Aluko A., Hou, Peter C., Hough, Catherine L., Iwashyna, Theodore J., Jackson, James C., Khan, Akram, Orun, Onur M., Patel, Mayur B., Raman, Rameela, Rice, Todd W., Ringwood, Nancy, Semler, Matthew W., Shapiro, Nathan I., Talmor, Daniel S., and Self, Wesley H.

Published
2021
Full Text
View/download PDF

35. Recall of clinical trial participation and attrition rates in survivors of acute respiratory distress syndrome

Author

Carlton, Erin F., Ice, Erin, Barbaro, Ryan P., Kampuis, Lee, Moss, Marc, Angus, Derek C., Banner-Goodspeed, Valerie M., Ginde, Adit A., Gong, Michelle N., Grissom, Colin K., Hou, Peter C., Huang, David T., Hough, Catherine Terri Lee, Talmor, Daniel S., Thompson, B. Taylor, Yealy, Donald M., Couper, Mick P., and Iwashyna, Theodore J.

Published
2021
Full Text
View/download PDF

37. Deep learning to detect acute respiratory distress syndrome on chest radiographs: a retrospective study with external validation

Author

Sjoding, Michael W, Taylor, Daniel, Motyka, Jonathan, Lee, Elizabeth, Co, Ivan, Claar, Dru, McSparron, Jakob I, Ansari, Sardar, Kerlin, Meeta Prasad, Reilly, John P, Shashaty, Michael G S, Anderson, Brian J, Jones, Tiffanie K, Drebin, Harrison M, Ittner, Caroline A G, Meyer, Nuala J, Iwashyna, Theodore J, Ward, Kevin R, and Gillies, Christopher E

Published
2021
Full Text
View/download PDF

38. Recovery after critical illness: putting the puzzle together-a consensus of 29.

Author

Azoulay, Elie, Vincent, Jean-Louis, Angus, Derek C, Arabi, Yaseen M, Brochard, Laurent, Brett, Stephen J, Citerio, Giuseppe, Cook, Deborah J, Curtis, Jared Randall, Dos Santos, Claudia C, Ely, E Wesley, Hall, Jesse, Halpern, Scott D, Hart, Nicholas, Hopkins, Ramona O, Iwashyna, Theodore J, Jaber, Samir, Latronico, Nicola, Mehta, Sangeeta, Needham, Dale M, Nelson, Judith, Puntillo, Kathleen, Quintel, Michael, Rowan, Kathy, Rubenfeld, Gordon, Van den Berghe, Greet, Van der Hoeven, Johannes, Wunsch, Hannah, and Herridge, Margaret

Subjects
Humans, Delirium, Critical Illness, Respiration, Artificial, Length of Stay, Consensus, Time Factors, Intensive Care Units, Deep Sedation, Pain Management, Long Term Adverse Effects, Cognitive dysfunction, Depression, Intensive care, Mechanical ventilation, Muscular disorder, Sedation, Traumatic stress, Weakness, Respiration, Artificial, Medical and Health Sciences, Emergency & Critical Care Medicine
Abstract

In this review, we seek to highlight how critical illness and critical care affect longer-term outcomes, to underline the contribution of ICU delirium to cognitive dysfunction several months after ICU discharge, to give new insights into ICU acquired weakness, to emphasize the importance of value-based healthcare, and to delineate the elements of family-centered care. This consensus of 29 also provides a perspective and a research agenda about post-ICU recovery.

Published
2017

39. Design and Rationale of the Reevaluation of Systemic Early Neuromuscular Blockade Trial for Acute Respiratory Distress Syndrome.

Author

Huang, David T, Angus, Derek C, Moss, Marc, Thompson, B Taylor, Ferguson, Niall D, Ginde, Adit, Gong, Michelle Ng, Gundel, Stephanie, Hayden, Douglas L, Hite, R Duncan, Hou, Peter C, Hough, Catherine L, Iwashyna, Theodore J, Liu, Kathleen D, Talmor, Daniel S, Yealy, Donald M, and Reevaluation of Systemic Early Neuromuscular Blockade Protocol Committee and the National Institutes of Health National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Network Investigators

Subjects
Reevaluation of Systemic Early Neuromuscular Blockade Protocol Committee and the National Institutes of Health National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Network Investigators, Humans, Respiratory Distress Syndrome, Adult, Atracurium, Neuromuscular Blocking Agents, Respiration, Artificial, Positive-Pressure Respiration, Neuromuscular Blockade, Mortality, Cause of Death, Feasibility Studies, Mental Recall, Muscle Strength, adult, clinical trial, interdisciplinary communication, methods, respiratory distress syndrome, Respiratory Distress Syndrome, Rare Diseases, Clinical Research, Patient Safety, Prevention, Clinical Trials and Supportive Activities, Lung, Acute Respiratory Distress Syndrome, Respiratory
Abstract

The Reevaluation of Systemic Early Neuromuscular Blockade (ROSE) trial is a multicenter, randomized trial designed to assess the efficacy and safety of early neuromuscular blockade in patients with moderate to severe acute respiratory distress syndrome. This document provides background for interpretation of the trial results, and highlights unique design approaches that may inform future trials of acute illness. We describe the process by which ROSE was chosen as the inaugural trial of the multidisciplinary Prevention and Early Treatment of Acute Lung Injury Network, provide the trial methodology using the Consolidated Standards of Reporting Trials framework, and discuss key design challenges and their resolution. Four key design issues proved challenging-feasibility, choice of sedation depth in the control group, impact of emphasizing early treatment on enrollment criteria and protocol execution, and choice of positive end-expiratory pressure strategy. We used literature, an iterative consensus model, and internal surveys of current practice to inform design choice. ROSE will provide definitive, Consolidated Standards of Reporting Trials adherent data on early neuromuscular blockade for future patients with acute respiratory distress syndrome. Our multidisciplinary approach to trial design may be of use to other trials of acute illness. Clinical trial registered with www.clinicaltrials.gov (NCT02509078).

Published
2017

40. Patient and Caregiver-Derived Health Service Improvements for Better Critical Care Recovery

Author

Haines, Kimberley J., Leggett, Nina, Hibbert, Elizabeth, Hall, Tarli, Boehm, Leanne M., Bakhru, Rita N., Bastin, Anthony J., Butcher, Brad W., Eaton, Tammy L., Harris, Wendy, Hope, Aluko A., Jackson, James, Johnson, Annie, Kloos, Janet A., Korzick, Karen A., Mactavish, Pamela, Meyer, Joel, Montgomery-Yates, Ashley, Quasim, Tara, Slack, Andrew, Wade, Dorothy, Still, Mary, Netzer, Giora, Hopkins, Ramona O., Mikkelsen, Mark E., Iwashyna, Theodore J., McPeake, Joanne, and Sevin, Carla M.

Published
2022
Full Text
View/download PDF

43. Impact of High-Dose Early Mobilization on Outcomes for Patients with Diabetes: A Secondary Analysis of the TEAM Trial.

Author

Serpa Neto, Ary, Bailey, Michael, Seller, Daniel, Agli, Alicia, Bellomo, Rinaldo, Brickell, Kathy, Broadley, Tessa, Buhr, Heidi, Gabbe, Belinda J., Gould, Doug W., Harrold, Meg, Higgins, Alisa M., Hurford, Sally, Iwashyna, Theodore J., Nichol, Alistair D., Presneill, Jeffrey J., Schaller, Stefan J., Sivasuthan, Janani, Tipping, Claire J., and Poole, Alex

Subjects
PEOPLE with diabetes, ODDS ratio, ARTIFICIAL respiration, LOGISTIC regression analysis, SECONDARY analysis
Abstract

Rationale: Patients with diabetes represent almost 20% of all ICU admissions and might respond differently to high-dose early active mobilization. Objectives: To assess whether diabetes modified the relationship between the dose of early mobilization on clinical outcomes in the TEAM trial. Methods: All TEAM trial patients were included. The primary outcome was days alive and out of the hospital at Day 180. Secondary outcomes included 180-day mortality and long-term functional outcomes at Day 180. Logistic and median regression models were used to explore the effect of high-dose early mobilization on outcomes by diabetes status. Measurements and Main Results: All 741 patients from the original trial were included. Of these, 159 patients (21.4%) had diabetes. Patients with diabetes had fewer days alive and out of the hospital at Day 180 (124 [0–153] vs. 147 [82–164]; P = 0.013) and higher 180-day mortality (30% vs. 18%; P = 0.044). In patients receiving high-dose early mobilization, the number of days alive and out of the hospital at Day 180 was 73.0 (0.0–144.5) in patients with diabetes and 146.5 (95.8–163.0) in patients without diabetes (P value for interaction = 0.108). However, in patients with diabetes, high-dose early mobilization increased the odds of mortality at 180 days (adjusted odds ratio, 3.47; 95% confidence interval, 1.67–7.61; P value for interaction = 0.001). Conclusions: In this secondary analysis of the TEAM trial, in patients with diabetes, a high-dose early mobilization strategy did not significantly decrease the number of days alive and out of the hospital at Day 180, but it increased 180-day mortality. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Author

Alexander, Peta, Barrett, Nicholas, Bělohlávek, Jan, Fisher, Dale, Fraser, John, Hssain, Ali Ait, Jung, Jae Sung, McMullan, Michael, Mehta, Yatin, Ogino, Mark T., Paden, Matthew L., Shekar, Kiran, Stead, Christine, Abu-Omar, Yasir, Agnoletti, Vanni, Akbar, Anzila, Alfoudri, Huda, Alviar, Carlos, Aronsky, Vladimir, August, Erin, Auzinger, Georg, Aveja, Hilda, Bakken, Rhonda, Balcells, Joan, Bangalore, Sripal, Barnes, Bernard W., Bautista, Alaiza, Bellows, Lorraine L., Beltran, Felipe, Benharash, Peyman, Benni, Marco, Berg, Jennifer, Bertini, Pietro, Blanco-Schweizer, Pablo, Brunsvold, Melissa, Budd, Jenny, Camp, Debra, Caridi-Scheible, Mark, Carton, Edmund, Casanova-Ghosh, Elena, Castleberry, Anthony, Chipongian, Christopher T., Choi, Chang Woo, Circelli, Alessandro, Cohen, Elliott, Collins, Michael, Copus, Scott, Coy, Jill, Crist, Brandon, Cruz, Leonora, Czuczwar, Mirosław, Daneshmand, Mani, Davis II, Daniel, De la Cruz, Kim, Devers, Cyndie, Duculan, Toni, Durham, Lucian, Elapavaluru, Subbarao, Elzo Kraemer, Carlos V., Filho, EDMÍLSON CARDOSO, Fitzgerald, Jillian, Foti, Giuseppe, Fox, Matthew, Fritschen, David, Fullerton, David, Gelandt, Elton, Gerle, Stacy, Giani, Marco, Goh, Si Guim, Govener, Sara, Grone, Julie, Guber, Miles, Gudzenko, Vadim, Gutteridge, Daniel, Guy, Jennifer, Haft, Jonathan, Hall, Cameron, Hassan, Ibrahim Fawzy, Herrán, Rubén, Hirose, Hitoshi, Ibrahim, Abdulsalam Saif, Igielski, Don, Ivascu, Felicia A., Izquierdo Blasco, Jaume, Jackson, Julie, Jain, Harsh, Jaiswal, Bhavini, Johnson, Andrea C., Jurynec, Jenniver A., Kellter, Norma M, Kohl, Adam, Kon, Zachary, Kredel, Markus, Kriska, Karen, Kunavarapu, Chandra, Lansink-Hartgring, Oude, LaRocque, Jeliene, Larson, Sharon Beth, Layne, Tracie, Ledot, Stephane, Lena, Napolitan, Lillie, Jonathan, Lotz, Gösta, Lucas, Mark, Ludwigson, Lee, Maas, Jacinta J., Maertens, Joanna, Mast, David, McCardle, Scott, McDonald, Bernard, McLarty, Allison, McMahon, Chelsea, Meybohm, Patrick, Meyns, Bart, Miller, Casey, Moraes Neto, Fernando, Morris, Kelly, Muellenbach, Ralf, Nicholson, Meghan, O'Brien, Serena, O'Keefe, Kathryn, Ogston, Tawnya, Oldenburg, Gary, Oliveira, Fabiana M., Oppel, Emily, Pardo, Diego, Parker, Sara J., Pedersen, Finn M., Pellecchia, Crescens, Pelligrini, Jose A.S., Pham, Thao T.N., Phillips, Ann R., Pirani, Tasneem, Piwowarczyk, Paweł, Plambeck, Robert, Pruett, William, Quandt, Brittany, Ramanathan, Kollengode, Rey, Alejandro, Reyher, Christian, Riera del Brio, Jordi, Roberts, Rachel, Roe, David, Roeleveld, Peter P., Rudy, Janet, Rueda, Luis F., Russo, Emanuele, Sánchez Ballesteros, Jesús, Satou, Nancy, Saueressig, Mauricio Guidi, Saunders, Paul C., Schlotterbeck, Margaret, Schwarz, Patricia, Scriven, Nicole, Serra, Alexis, Shamsah, Mohammad, Sim, Lucy, Smart, Alexandra, Smith, Adam, Smith, Deane, Smith, Maggie, Sodha, Neel, Sonntagbauer, Michael, Sorenson, Marc, Stallkamp, Eric B, Stewart, Allison, Swartz, Kathy, Takeda, Koji, Thompson, Shaun, Toy, Bridget, Tuazon, Divina, Uchiyama, Makoto, Udeozo, Obiora I., van Poppel, Scott, Ventetuolo, Corey, Vercaemst, Leen, Vinh Chau, Nguyen V., Wang, I-Wen, Williamson, Carrie, Wilson, Brock, Winkels, Helen, Barbaro, Ryan P, MacLaren, Graeme, Boonstra, Philip S, Iwashyna, Theodore J, Slutsky, Arthur S, Fan, Eddy, Bartlett, Robert H, Tonna, Joseph E, Hyslop, Robert, Fanning, Jeffrey J, Rycus, Peter T, Hyer, Steve J, Anders, Marc M, Agerstrand, Cara L, Hryniewicz, Katarzyna, Diaz, Rodrigo, Lorusso, Roberto, Combes, Alain, and Brodie, Daniel

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results